This is Moderna's Canada website
It may contain content that is not applicable to your location
Welcome to Moderna’s Canadian mRNA manufacturing facility
This state-of-the-art facility is dedicated to manufacturing mRNA vaccines right here in Canada, with Canadians as the first priority. On track for LEED Silver certification and the first pharmaceutical site to join Canada’s Net-Zero Challenge, it reflects our commitment to innovation, sustainability, and national health resilience.
About the facility
Location: Laval, Quebec
Manufacturing facility footprint: 100,000 SF
Construction completion: February 23, 2024
Manufacturing capability: Up to 30 million doses annually (100 million doses in a pandemic—enough to vaccinate the Canadian population more than 2.5 times)
Commercial Manufacturing Support Groups
Digital
Environmental Health and Safety
Facilities and Engineering
Manufacturing Science and Technology
Quality Assurance
Quality Control
Supply Chain
Validation
A Strategic Partnership for National Resilience
Moderna has proudly invested in Canada including funding the construction of our Laval manufacturing facility, expanding our workforce, and advancing local R&D. We are grateful for our partnership with the Government of Canada as we work together to strengthen national pandemic preparedness and ensure timely access to lifesaving mRNA vaccines—made in Canada, for Canadians.